Showing 8021-8030 of 8350 results for "".
- Jonah Shacknai Honored at Cosmetic Surgery Forumhttps://practicaldermatology.com/news/20121203-jonah_shacknai_honored_at_cosmetic_surgery_forum/2459670/Innovators in the field of cosmetic dermatology were honored this past weekend at Cosmetic Surgery Forum, a discussion-based CME symposium held in Las Vegas and now in its fourth year. Jonah Shacknai, Founder of Medicis, was the recipient of the Lifetime Achievement in Dermatology Award. On receivin
- Physician Income "Disappointing," But Up Slightlyhttps://practicaldermatology.com/news/20121121-physician_income_disappointing_but_up_slightly/2459674/Although most physicians report that their net income is "disappointing," American physicians saw a slight uptick in income in 2012 compared to 2011, a new report shows. Specialists continue to outpace primary care physicians; 40% of the latter make less than $150,000 per year,
- Sun Pharmaceutical to Buy DUSA Pharmaceuticalshttps://practicaldermatology.com/news/20121118-sun_pharmaceutical_to_buy_dusa_pharmaceuticals/2459678/Sun Pharmaceutical Industries Ltd. will buy DUSA Pharmaceuticals Inc. for about $215 million in cash, as the India-based company looks to make a foray into the lucrative market for dermatological treatments. The deal has been unanimously approved by the boards of both companies and DUSA's board has
- Murad Names Fred Gysi Chief Financial Officerhttps://practicaldermatology.com/news/20121115-murad_names_fred_gysi_chief_financial_officer/2459682/Fred Gysi now serves as Chief Financial Officer for Murad. In this role, Gysi will be responsible for financial reporting, budgeting, treasury and cash flow management, financial and marketing analysis, and strategic planning. Gysi comes to Murad w
- Cosmetic Surgery Forum Names Honoreeshttps://practicaldermatology.com/news/20121101-cosmetic_surgery_forum_names_honorees/2459685/Richard Fitzpatrick, MD and Diane Ranger, founder of Colorescience, will receive the “Innovators in Dermatology Award” at Cosmetic Surgery Forum 2012 in Las Vegas, November 29 through December 1. Jonah Schacknai, Founder and CEO of Medicis Pharmaceuticals, will receive the Lifetime Service Award. Re
- Provectus Presents Data on PV-10 in Combination with Systemic Chemotherapyhttps://practicaldermatology.com/news/20121029-provectus_presents_data_on_pv-10_in_combination_with_systemic_chemotherapy/2459688/Provectus Pharmaceuticals, Inc. presented nonclinical data on PV-10 at the Society for Immunotherapy of Cancer (SITC) 27th Annual Meeting on October 26 and 27, 2012 in North Bethesda, MD. PV-10 is Provectus Pharmaceuticals' novel oncology drug design
- Dermatologist Launches Rx Rebates, LLChttps://practicaldermatology.com/news/20121029-dermatologist_launches_rx_rebates_llc/2459690/Joel Bain Herron, MD, a dermatologist with Northeast Dermatology & Cosmetic Surgery Center, LLC in Gahanna, OH, founded Rx Rebates, LLC, a technology company. The website Rx_Rebates.com will be a mobile accessible site with a searchable database of digital versions of branded prescription rebate car
- TURO SKIN System Launchedhttps://practicaldermatology.com/news/20121018-turo_skin_system_launched/2459701/Founder and CEO John Renucci, MD, created TURO SKIN, a simplified skincare system for men, which has now been released. The collection offers solutions for face, shave, hair, and body. TURO SKIN products are available online at www.turoskin.com an
- OIG Report: CMS Fails to Lessen Medicare Financial Losseshttps://practicaldermatology.com/news/20121012-oig_report_cms_fails_to_lessen_medicare_financial_losses/2459709/CMS failed to satisfy the legal requirements developed to lessen financial losses to Medicare, despite the agency's notification of the almost 14,000 Medicare beneficiaries whose health identities were compromised in 14 security breaches between Sept. 23, 2009, and Dec. 31, 2011, according to a repo
- Revance Regains Rights to Its Botulinum Toxinshttps://practicaldermatology.com/news/20121009-revance_regains_rights_to_its_botulinum_toxins/2459713/Revance Therapeutics, Inc. announced a settlement and termination agreement for its contractual relationships with Medicis Pharmaceutical Corporation concerning RT001 Botulinum Toxin Type A Topical Gel and RT002 Injectable Botulinum Toxin Type A.